Angiochem is a clinical-stage biotechnology company discovering and developing novel drugs that are crossing the blood-brain barrier to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain diseases including brain cancers, lysosomal storage disorders, pain and others. The EPiC platform has been strongly validated in humans.
Founded date: 2003
Investors 2
| Date | Name | Website |
| - | Aligo Inno... | technology... |
| - | BDC | bdc.ca/ |
Mentions in press and media 2
| Date | Title | Description |
| 27.02.2012 | GSK partners with Angiochem on drugs that penetrate the blood-brain barrier | Angiochem receives $31.5 million up front under the agreement with GSK. Including that payment, the company stands to gain more than $300 million in research funding and other payments if GSK pursues additional LSD targets developed in the ... |
| - | GSK partners with Angiochem on drugs that penetrate the blood-brain barrier | GlaxoSmithKline (NYSE:GSK) is moving to address rare, inherited disorders such as Tay-Sachs disease through a new drug partnership with Angiochem. The companies will work together to discover and develop treatments for lysosomal storage dis... |